ADA-07 suppresses solar ultraviolet–induced skin carcinogenesis by directly inhibiting TOPK

Ge Gao, Tianshun Zhang, Qiushi Wang, Kanamata Reddy, Hanyong Chen, Ke Yao, Keke Wang, Eunmiri Roh, Tatyana Zykova, Weiya Ma, Joohyun Ryu, Clara Curiel-Lewandrowski, David Alberts, Sally E. Dickinson, Ann M. Bode, Ying Xing, Zigang Dong

Research output: Research - peer-reviewArticle

Abstract

Cumulative exposure to solar ultraviolet (SUV) irradiation is regarded as the major etiologic factor in the development of skin cancer. The activation of the MAPK cascades occurs rapidly and is vital in the regulation of SUV-induced cellular responses. The T-LAK cell–originated protein kinase (TOPK), an upstream activator of MAPKs, is heavily involved in inflammation, DNA damage, and tumor development. However, the chemopreventive and therapeutic effects of specific TOPK inhibitors in SUV-induced skin cancer have not yet been elucidated. In the current study, ADA-07, a novel TOPK inhibitor, was synthesized and characterized. Pull-down assay results, ATP competition, and in vitro kinase assay data revealed that ADA-07 interacted with TOPK at the ATP-binding pocket and inhibited its kinase activity. Western blot analysis showed that ADA-07 suppressed SUV-induced phosphorylation of ERK1/2, p38, and JNKs and subsequently inhibited AP-1 activity. Importantly, topical treatment with ADA-07 dramatically attenuated tumor incidence, multiplicity, and volume in SKH-1 hairless mice exposed to chronic SUV. Our findings suggest that ADA-07 is a promising chemopreventive or potential therapeutic agent against SUV-induced skin carcinogenesis that acts by specifically targeting TOPK.

LanguageEnglish (US)
Pages1843-1854
Number of pages12
JournalMolecular Cancer Therapeutics
Volume16
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Lymphokine-Activated Killer Cells
Protein Kinases
Carcinogenesis
Skin
Skin Neoplasms
Protein Kinase Inhibitors
Phosphotransferases
Adenosine Triphosphate
Neoplasms
Hairless Mouse
Transcription Factor AP-1
Therapeutic Uses
DNA Damage
Western Blotting
Phosphorylation
Inflammation
Incidence
Therapeutics
In Vitro Techniques

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gao, G., Zhang, T., Wang, Q., Reddy, K., Chen, H., Yao, K., ... Dong, Z. (2017). ADA-07 suppresses solar ultraviolet–induced skin carcinogenesis by directly inhibiting TOPK. Molecular Cancer Therapeutics, 16(9), 1843-1854. DOI: 10.1158/1535-7163.MCT-17-0212

ADA-07 suppresses solar ultraviolet–induced skin carcinogenesis by directly inhibiting TOPK. / Gao, Ge; Zhang, Tianshun; Wang, Qiushi; Reddy, Kanamata; Chen, Hanyong; Yao, Ke; Wang, Keke; Roh, Eunmiri; Zykova, Tatyana; Ma, Weiya; Ryu, Joohyun; Curiel-Lewandrowski, Clara; Alberts, David; Dickinson, Sally E.; Bode, Ann M.; Xing, Ying; Dong, Zigang.

In: Molecular Cancer Therapeutics, Vol. 16, No. 9, 01.09.2017, p. 1843-1854.

Research output: Research - peer-reviewArticle

Gao, G, Zhang, T, Wang, Q, Reddy, K, Chen, H, Yao, K, Wang, K, Roh, E, Zykova, T, Ma, W, Ryu, J, Curiel-Lewandrowski, C, Alberts, D, Dickinson, SE, Bode, AM, Xing, Y & Dong, Z 2017, 'ADA-07 suppresses solar ultraviolet–induced skin carcinogenesis by directly inhibiting TOPK' Molecular Cancer Therapeutics, vol 16, no. 9, pp. 1843-1854. DOI: 10.1158/1535-7163.MCT-17-0212
Gao G, Zhang T, Wang Q, Reddy K, Chen H, Yao K et al. ADA-07 suppresses solar ultraviolet–induced skin carcinogenesis by directly inhibiting TOPK. Molecular Cancer Therapeutics. 2017 Sep 1;16(9):1843-1854. Available from, DOI: 10.1158/1535-7163.MCT-17-0212
Gao, Ge ; Zhang, Tianshun ; Wang, Qiushi ; Reddy, Kanamata ; Chen, Hanyong ; Yao, Ke ; Wang, Keke ; Roh, Eunmiri ; Zykova, Tatyana ; Ma, Weiya ; Ryu, Joohyun ; Curiel-Lewandrowski, Clara ; Alberts, David ; Dickinson, Sally E. ; Bode, Ann M. ; Xing, Ying ; Dong, Zigang. / ADA-07 suppresses solar ultraviolet–induced skin carcinogenesis by directly inhibiting TOPK. In: Molecular Cancer Therapeutics. 2017 ; Vol. 16, No. 9. pp. 1843-1854
@article{2fab999508b544f2a434cd591540e0c3,
title = "ADA-07 suppresses solar ultraviolet–induced skin carcinogenesis by directly inhibiting TOPK",
abstract = "Cumulative exposure to solar ultraviolet (SUV) irradiation is regarded as the major etiologic factor in the development of skin cancer. The activation of the MAPK cascades occurs rapidly and is vital in the regulation of SUV-induced cellular responses. The T-LAK cell–originated protein kinase (TOPK), an upstream activator of MAPKs, is heavily involved in inflammation, DNA damage, and tumor development. However, the chemopreventive and therapeutic effects of specific TOPK inhibitors in SUV-induced skin cancer have not yet been elucidated. In the current study, ADA-07, a novel TOPK inhibitor, was synthesized and characterized. Pull-down assay results, ATP competition, and in vitro kinase assay data revealed that ADA-07 interacted with TOPK at the ATP-binding pocket and inhibited its kinase activity. Western blot analysis showed that ADA-07 suppressed SUV-induced phosphorylation of ERK1/2, p38, and JNKs and subsequently inhibited AP-1 activity. Importantly, topical treatment with ADA-07 dramatically attenuated tumor incidence, multiplicity, and volume in SKH-1 hairless mice exposed to chronic SUV. Our findings suggest that ADA-07 is a promising chemopreventive or potential therapeutic agent against SUV-induced skin carcinogenesis that acts by specifically targeting TOPK.",
author = "Ge Gao and Tianshun Zhang and Qiushi Wang and Kanamata Reddy and Hanyong Chen and Ke Yao and Keke Wang and Eunmiri Roh and Tatyana Zykova and Weiya Ma and Joohyun Ryu and Clara Curiel-Lewandrowski and David Alberts and Dickinson, {Sally E.} and Bode, {Ann M.} and Ying Xing and Zigang Dong",
year = "2017",
month = "9",
doi = "10.1158/1535-7163.MCT-17-0212",
volume = "16",
pages = "1843--1854",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - ADA-07 suppresses solar ultraviolet–induced skin carcinogenesis by directly inhibiting TOPK

AU - Gao,Ge

AU - Zhang,Tianshun

AU - Wang,Qiushi

AU - Reddy,Kanamata

AU - Chen,Hanyong

AU - Yao,Ke

AU - Wang,Keke

AU - Roh,Eunmiri

AU - Zykova,Tatyana

AU - Ma,Weiya

AU - Ryu,Joohyun

AU - Curiel-Lewandrowski,Clara

AU - Alberts,David

AU - Dickinson,Sally E.

AU - Bode,Ann M.

AU - Xing,Ying

AU - Dong,Zigang

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Cumulative exposure to solar ultraviolet (SUV) irradiation is regarded as the major etiologic factor in the development of skin cancer. The activation of the MAPK cascades occurs rapidly and is vital in the regulation of SUV-induced cellular responses. The T-LAK cell–originated protein kinase (TOPK), an upstream activator of MAPKs, is heavily involved in inflammation, DNA damage, and tumor development. However, the chemopreventive and therapeutic effects of specific TOPK inhibitors in SUV-induced skin cancer have not yet been elucidated. In the current study, ADA-07, a novel TOPK inhibitor, was synthesized and characterized. Pull-down assay results, ATP competition, and in vitro kinase assay data revealed that ADA-07 interacted with TOPK at the ATP-binding pocket and inhibited its kinase activity. Western blot analysis showed that ADA-07 suppressed SUV-induced phosphorylation of ERK1/2, p38, and JNKs and subsequently inhibited AP-1 activity. Importantly, topical treatment with ADA-07 dramatically attenuated tumor incidence, multiplicity, and volume in SKH-1 hairless mice exposed to chronic SUV. Our findings suggest that ADA-07 is a promising chemopreventive or potential therapeutic agent against SUV-induced skin carcinogenesis that acts by specifically targeting TOPK.

AB - Cumulative exposure to solar ultraviolet (SUV) irradiation is regarded as the major etiologic factor in the development of skin cancer. The activation of the MAPK cascades occurs rapidly and is vital in the regulation of SUV-induced cellular responses. The T-LAK cell–originated protein kinase (TOPK), an upstream activator of MAPKs, is heavily involved in inflammation, DNA damage, and tumor development. However, the chemopreventive and therapeutic effects of specific TOPK inhibitors in SUV-induced skin cancer have not yet been elucidated. In the current study, ADA-07, a novel TOPK inhibitor, was synthesized and characterized. Pull-down assay results, ATP competition, and in vitro kinase assay data revealed that ADA-07 interacted with TOPK at the ATP-binding pocket and inhibited its kinase activity. Western blot analysis showed that ADA-07 suppressed SUV-induced phosphorylation of ERK1/2, p38, and JNKs and subsequently inhibited AP-1 activity. Importantly, topical treatment with ADA-07 dramatically attenuated tumor incidence, multiplicity, and volume in SKH-1 hairless mice exposed to chronic SUV. Our findings suggest that ADA-07 is a promising chemopreventive or potential therapeutic agent against SUV-induced skin carcinogenesis that acts by specifically targeting TOPK.

UR - http://www.scopus.com/inward/record.url?scp=85029456589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029456589&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-17-0212

DO - 10.1158/1535-7163.MCT-17-0212

M3 - Article

VL - 16

SP - 1843

EP - 1854

JO - Molecular Cancer Therapeutics

T2 - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 9

ER -